Literature DB >> 3032092

Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture.

G Abele, A Karlström, J Harmenberg, S Shigeta, A Larsson, B Lindborg, B Wahren.   

Abstract

The activity and mode of action of the new nucleoside analog (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (2HM-HBG) against varicella-zoster virus (VZV) were determined. In cell culture, replication of different strains of VZV was inhibited to 50% by 0.4 to 0.7 microM 2HM-HBG, while 685 microM was required to inhibit 50% of the DNA synthesis in uninfected human lung fibroblasts. A thymidine kinase-negative VZV strain was not inhibited by 100 microM 2HM-HBG. Inhibition of VZV replication was not reversible after 7 to 14 days of incubation, depending on the multiplicity of VZV. 2HM-HBG was shown to be selectively phosphorylated by purified VZV thymidine kinase, with an inhibition constant of 32.5 microM. The antiviral activity of 2HM-HBG in cell culture was decreased by the addition of deoxythymidine and deoxycytidine but not by other ribo- or deoxyribonucleosides.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032092      PMCID: PMC174655          DOI: 10.1128/AAC.31.1.76

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Acyclic guanosine analogs as substrates for varicella-zoster virus thymidine kinase.

Authors:  A R Karlström; C F Källander; G Abele; A Larsson
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

2.  A mutant strain of varicella-zoster virus deficient in thymidine kinase-inducing activity.

Authors:  T Yokota; M Ogata; S Shigeta
Journal:  Fukushima J Med Sci       Date:  1983-07

Review 3.  Interactions between virus and antiviral compounds in the host cell.

Authors:  J Harmenberg
Journal:  Med Biol       Date:  1984

4.  Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine.

Authors:  D H Shepp; P S Dandliker; J D Meyers
Journal:  N Engl J Med       Date:  1986-01-23       Impact factor: 91.245

5.  Development of sensitive and enzyme-linked immunoassays for herpesvirus antigens and some applications.

Authors:  V A Sundqvist; B Wahren
Journal:  Dev Biol Stand       Date:  1982

6.  Computer-based virus sensitivity assay and neutralization method. Applications for herpesviruses.

Authors:  B Wahren; P Wahren; J Harmenberg; V A Sundqvist
Journal:  J Virol Methods       Date:  1983-05       Impact factor: 2.014

7.  Rapid diagnosis of varicella-zoster virus infection by detection of viral deoxythymidine kinase in serum and vesicle fluid.

Authors:  C F Källander; J S Gronowitz; E Olding-Stenkvist
Journal:  J Clin Microbiol       Date:  1983-02       Impact factor: 5.948

8.  Intracellular pools of thymidine reduce the antiviral action of acyclovir.

Authors:  J Harmenberg
Journal:  Intervirology       Date:  1983       Impact factor: 1.763

9.  Inhibitory effects of foscarnet on herpesvirus multiplication in cell culture.

Authors:  J Schnürer; B Oberg
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

10.  Influence of cells and virus multiplicity on the inhibition of herpesviruses with acycloguanosine.

Authors:  J Harmenberg; B Wahren; B Oberg
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

View more
  12 in total

1.  Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine.

Authors:  T I Ng; Y Shi; H J Huffaker; W Kati; Y Liu; C M Chen; Z Lin; C Maring; W E Kohlbrenner; A Molla
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

Review 3.  Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy.

Authors:  Erik De Clercq; Hugh J Field
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate.

Authors:  G Abele; B Eriksson; J Harmenberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

5.  Improvement of the absorption of oral (R,S)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine, an anti-varicella-zoster virus drug, in rats and monkeys.

Authors:  D M Lake-Bakaar; B Lindborg; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

6.  Efficacy of (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virus.

Authors:  K F Soike; R Bohm; J L Huang; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

7.  The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil.

Authors:  J Neyts; G Andrei; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

8.  Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug.

Authors:  D M Lake-Bakaar; G Abele; B Lindborg; K F Soike; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

9.  Antiherpesvirus activity and mechanism of action of indolo-(2,3-b)quinoxaline and analogs.

Authors:  J Harmenberg; B Wahren; J Bergman; S Akerfeldt; L Lundblad
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

10.  Effect of (r)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) and AZT-lipid-PFA on human herpesvirus-6B infected cells.

Authors:  Karen Yao; Christel Hoest; Farzin Rashti; Timm C Schott; Steven Jacobson
Journal:  J Clin Virol       Date:  2009-06-12       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.